NovoCure Limited Stock News

Banque Cantonale Vaudoise acquired a new position in shares of Novocure Ltd (NASDAQ:NVCR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The

Advisory Research Inc. raised its position in Novocure Ltd (NASDAQ:NVCR) by 59.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 40,618 s

Acadian Asset Management LLC purchased a new stake in Novocure Ltd (NASDAQ:NVCR) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fun

Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo Wells Fargo BAX BDX COO JNJ NVCR PEN

Zai Lab price target raised to $71.46 from $48.32 at Macquarie Macquarie ZLAB

Novocure Ltd (NASDAQ:NVCR) – Stock analysts at SunTrust Banks dropped their FY2021 EPS estimates for Novocure in a note issued to investors on Thursday, February 27th. SunTrust Banks analyst G. Gilb

Novocure Ltd (NASDAQ:NVCR) insider Pritesh Shah sold 5,067 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $81.16, for a total val

NVCR earnings call for the period ending December 31, 2019.

Cambridge Investment Research Advisors Inc. bought a new stake in Novocure Ltd (NASDAQ:NVCR) during the fourth quarter, according to the company in its most recent filing with the Securities and Excha

Novocure (NASDAQ:NVCR)‘s stock had its “buy” rating reiterated by research analysts at Mizuho in a note issued to investors on Friday, AnalystRatings.com reports. They currently have a $91.00 pr

Mizuho Securities analyst Difei Yang maintained a Buy rating on NovoCure (NVCR) today and set a price target of $91.00. The company's shares closed last

Mizuho Securities analyst Difei Yang maintained a Buy rating on NovoCure ( NVCR – Research Report ) today and set a price target of $91.00 . The company’s shares closed last Monday at $77.28. Acco

In a report released today, Esther Rajavelu from Oppenheimer maintained a Buy rating on NovoCure (NVCR), with a price target of $102.00. The company's

In a report released today, Esther Rajavelu from Oppenheimer maintained a Buy rating on NovoCure ( NVCR – Research Report ), with a price target of $102.00 . The company’s shares closed last Monda

Shares initially plunged following the company's quarterly results. Were the numbers bad, or is something else impacting the stock price?